EBITDA Margin % is calculated as EBITDA divided by its Revenue. Excelsior Biopharma's EBITDA for the
three
months ended in Dec. 2025 was NT$-13.4 Mil. Excelsior Biopharma's Revenue for the
three
months ended in Dec. 2025 was NT$279.2 Mil. Therefore, Excelsior Biopharma's EBITDA margin for the quarter that ended in Dec. 2025 was -4.80%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Excelsior Biopharma EBITDA Margin % Related Terms
Excelsior Biopharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Excelsior Biopharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Excelsior Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Excelsior Biopharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Excelsior Biopharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Excelsior Biopharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Excelsior Biopharma (ROCO:6496) has a EBITDA Margin % of -4.80% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Excelsior Biopharma and its competitors. According to the industry distribution chart, Excelsior Biopharma ranks #777 out of 952 companies in the Drug Manufacturers industry, placing it in the top 81.6%.
Is Excelsior Biopharma's EBITDA Margin % too high?
Excelsior Biopharma's current EBITDA Margin % is -4.80%. Based on the distribution chart, Excelsior Biopharma ranks #777 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Excelsior Biopharma has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Excelsior Biopharma's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Excelsior Biopharma ranks #777 out of 952 companies for EBITDA Margin %. This places Excelsior Biopharma in the lower half of its industry. The industry median EBITDA Margin % is 12.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Excelsior Biopharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Excelsior Biopharma's current EBITDA Margin % is -4.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Excelsior Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Excelsior Biopharma (ROCO:6496) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$35.81, compared to a current price of NT$25.30 — trading 29.3% below its estimated fair value. The current EBITDA Margin % is -4.80%. Excelsior Biopharma's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Excelsior Biopharma (ROCO:6496), the current EBITDA Margin % is -4.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Excelsior Biopharma (ROCO:6496) Overvalued in 2026?
Based on GuruFocus' analysis, Excelsior Biopharma stock appears to be undervalued.
The current stock price of NT$25.30 is trading 29.3% below its estimated GF Value™ of NT$35.81.
GuruFocus considers Excelsior Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:6496:
EBITDA Margin %: -4.80%
GF Value™: NT$35.81 vs. price of NT$25.30 (29.3% below fair value)
No single metric tells the full story. See the ROCO:6496 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, food, cosmecteuticals and development of cosmetics, research, importing, and exporting of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.
54GF Score
Get the complete analysis for ROCO:6496
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6496 has been successfully added to your 
